0.5814  -0.008 (-1.29%)		06-20 15:11
Open: 0.5883 High: 0.5905 Volume: 83,889		Pre. Close: 0.589 Low: 0.58 Market Cap: 25(M)

Short term
Mid term
Targets	6-month :	0.67	1-year :	0.79
Resists	First :	0.57	Second :	0.67
Pivot price	0.56
Supports	First :	0.55	Second :	0.54
MAs	MA(5) :	0.56	MA(20) :	0.56
	MA(100) :	0.52	MA(250) :	0.48
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	52.4	D(3) :	55
RSI	RSI(14): 53.5
52-week	High :	0.57	Low :	0.3

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MTCR ] has closed below upper band by 30.4%. Bollinger Bands are 46.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.58 - 0.58	0.58 - 0.58
Low:	0.55 - 0.56	0.56 - 0.56
Close:	0.56 - 0.57	0.57 - 0.57

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Thu, 18 Apr 2024
METACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates ... - The Globe and Mail

Fri, 23 Dec 2022
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement - Yahoo Finance

Tue, 06 Sep 2022
Equillium to Acquire Metacrine in All-Stock Transaction - Business Wire

Thu, 03 Mar 2022
Nuvectis Pharma Inc. (NASDAQ: NVCT) Announce Publication of An Article Highlighting Robust Activity of NXP900 - BP Journal

Fri, 22 Oct 2021
The Race is Heating Up in the $30-plus Billion NASH Treatment Space (MDGL, ATRX, VKTX, ARWR, GALT, MTCR ... - BP Journal

Thu, 21 Oct 2021
Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re ... - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	44 (M)
Shares Float	24 (M)
Held by Insiders	14.7 (%)
Held by Institutions	37.1 (%)
Shares Short	87 (K)
Shares Short P.Month	105 (K)

EPS	-1.03
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.87
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-36.9 %
Return on Equity (ttm)	-90.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-1.04
Sales Per Share	0
EBITDA (p.s.)	-0.83
Qtrly Earnings Growth	0 %
Operating Cash Flow	-36 (M)
Levered Free Cash Flow	-21 (M)

PE Ratio	-0.56
PEG Ratio	0
Price to Book value	0.65
Price to Sales	0
Price to Cash Flow	-0.69

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.